Work

Medical Castration With LHRH Agonists: 25 Years Later With Major Benefits Achieved on Survival in Prostate Cancer

Year: 2004
Type: review
Abstract: Prostate cancer is the most frequently diagnosed cancer and the second cause of cancer death in men in North America (Jemal et al, 2003).In fact, one of eight men will be diagnosed with prostate cancer during his lifetime.At such a rate, prostate cancer will kill more than 3 000 000 men among the male population presently living in the United States, whereas more than 200 000 men die annually worldwide from prostate cancer.The medical and social consequences of this disease are comparable to those of breast cancer in women.Prostate cancer is thus a major challenge in urgent need of significant improvement in diagnosis and treatment. Limitations of Surgical Castration and High Doses of EstrogensAlthough it is known today that surgical castration and high-dose estrogen (monotherapy) discovered by Huggins (Huggins and Hodges, 1941) is limited to blockade of the androgens of testicular origin, a long series of reports has shown that such treatment achieves a positive response in as many as 60% to 70% of advanced prostate cancer patients, although for a limited period of time (Nesbit and Baum, 1950;Staubitz et al, 1954;VACURG, 1967;Mettlin et al, 1982;Murphy et al, 1983).As indicated by such a high proportion of positive responses observed after only partial blockade of androgens, prostate cancer is highly sensitive to endocrine therapy.In fact, prostate cancer is the most sensitive of all hormone-sensitive cancers to endocrine therapy.The serious and frequently lethal cardiovascular and
Language: English
Subfield: Cancer Research
Open Access status: bronze
OpenAlex ID: W1511220590
FWCI: 0.073
Cites: 54
Cited by: 31
Related to: 10